Abstract: A comparative plasma pharmacokinetics/Pharmacodynamic modeling of enrofloxacin following administration of three brands of 10% enrofloxacin was studied in healthy broiler chickens using a randomized and parallel design. Pre-treatment and post-treatment samples were obtained from brachial or right jugular veins after having administered 20 mg/kg b.w of enrofloxacin at 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h. Plasma samples were analyzed for enrofloxacin concentration by a simple agar disk diffusion microbiological assay. Selected pharmacokinetics parameters were calculated using a non-compartmental model. There was a significant difference in the plasma concentration-time and pharmacokinetics profiles (p<0.05) of the three brands. But the plasma concentrations of enrofloxacin exceeded the MIC for most respectively. This correlates with high efficacy and reduced chances for the development of resistant pathogenic bacterial organisms following oral administration of these brands of enrofloxacin oral formulations in broiler chickens.
INTRODUCTION
Enrofloxacin, a Fluoroquinolone, bactericidal and broad spectrum antibiotic is used exclusively in Veterinary medicine for the treatment of septicemia, respiratory tract, urinary tract, skin, soft tissues, bone and joint infections (Sanjib et al., 2005) . In many countries enrofloxacin is being used as the routine choice to treat almost any bacterial disease in poultry (Sumano and Gutierrez, 2000; Sumano and Gutierrez, 2001) . Since Fluoroquinolones generally exhibit concentrationdependent effect, its activity increases with increasing concentrations at its sites of action (Craig, 1993; Mouton and Tulkens, 2005) . Knowledge of disposition kinetic of antibacterial agents alone is inadequate in predicting their therapeutic efficacies. Thus, a Pharmacokinetics/ Pharmacodynamics (PK/PD) integration is critical i n relating the exposure (PK) and response (PD) to drug, which could be desirable or undesirable (Reiko et al., 2006) . It also establishes a mathematical and theoretical link between PK and PD and helps better predict drug action (Lakshmi, 2006) . The pharmacokinetic parameters most frequently used for PK/PD modeling in concentration-dependent antimicrobials are those which reflect an increase in drug concentration and exposure, C and AUC (Baggot, max 2001; Mouton and Tulkens, 2005) . The biomarkers commonly linked to clinical outcome of antimicrobials are the ratio of peak plasma concentration of drug to minimum inhibition concentration, C /MIC; the ratio of max 24-h area under the plasma concentration-time curve to minimum inhibition concentration, AUC /MIC and the duration of time that plasma levels exceed the minimum inhibition concentration, T >MIC (Baggot, 2001; Marie, 2007) . Clinical response usually correlates with AUC /MIC and C /MIC for concentration-dependent 0-24 max antimicrobial agents, but the latter, C /MIC is found to max be relatively more important for Fluoroquinolones where the ratio of about 5-10 has been associated with high efficacy and lower incidence of developing bacterial resistance (Baggot, 2001) . Other modeling studies revealed that survival of the host and minimized risk of the emergence of resistant bacterial strains is linked to C /MIC when the ratio is equal or greater than 10 max (Meinen et al., 1995; Dowling et al., 1995; Mouton and Tulkens, 2005) . Because of high prevalence of enrofloxacin sensitive bacterial infections in poultry, scarcity and high cost of the pioneer product (Baytril ), there has been a ® tremendous increase in the use of other brands o f enrofloxacin. With increasing availability and use o f generic enrofloxacin products from different pharmaceutical companies, practitioners are faced with the dilemma of therapeutic failures and side effects following the use of some of these arrays of multisource products in the market. Since these clinical These were stored at -4 C and analyzed 24 h following conditions results in great economic losses to farmers and the pioneer formulations and few brands have severally proven effective, there is a need to investigate the main surrogate efficacy marker, C /MIC using MIC max 90
against the most common pathogenic bacterial organisms in poultry (Sanjib et al., 2005) . (Bryant, 1981; Dowling et al., 1995 carefully and firmly placed onto the surface of the E. colifrom Zaria were used as the media and test seeded nutrient agar (n = 3). This was allowed to diffuse microorganism respectively.
MATERIALS AND METHODS
for 5 min after which they were incubated at 37 C in an
Experimental subjects: Thirty six broiler chickens, 8 diameters of zones of inhibition were measured with the weeks old, weighing 2.5-3.0 kg body weight (b.w) were aid of a transparent rule to the nearest millimeter. Each used. They were purchased as day old chicks from a sample was analyzed in triplicate. hatchery in Ibadan, Nigeria and managed under deep A seven-point standard curve was constructed by spiking litter system. They were vaccinated against most blank chicken plasma with concentrations of analytical common infectious poultry diseases. The feed was enrofloxacin salt ranging from 0.02-5.00 µg/ml. A linear formulated without inclusion of drugs. At 5 weeks old, curve of plasma enrofloxacin concentrations versus the apparently healthy chickens were separated and diameters of inhibition zones was obtained (R = 0.89). allowed to acclimatize in the experimental environment Plasma concentrations of enrofloxacin were determined for t hree weeks during which no drug, except by comparing the zone of inhibition diameters with the multivitamins was administered to them. standard curve. The absence of interfering endogenous
Experimental design: A randomized, single oral dose, plasma obtained at time 0 (pretreatment) which showed parallel method was adopted. The animals were no visible zone of inhibition around the impregnated assigned to three groups; A, B and C of 12 animals disks. The Limit of Quantification (LOQ) was defined each. Feeds and water were withdrawn 8 and 2-h visually as the smallest amount of drug that produced a respectively before drug administration. This was t o clearly distinguishable zone of inhibition around the reduce absorption variability due to drug-feed interaction edges of enrofloxacin-saturated disks on nutrient agar and over dilution of the drug respectively (Randandt et media and was estimated to be 0.02 µg/ml (Andres et al., 1992) . Animals in groups A, B and C were weighed al., 2009). individually and administered by gavage conflox -vet, ® kenflox and pulmotryl brands of 10% enrofloxacin oral ® ® formulations respectively at a dose level of 20 mg/kg b.w. The animals were monitored and those that regurgitated were excluded from the experiment. Thereafter, feeds and water were re-introduced 2 h post drug administration.
Sampling and processing: Blood samples were obtained by venupuncture through the left jugular or brachial veins into EDTA tubes at times 0 (pre treatment), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24-h (post treatment) . It was ensured that the differences between the targeted and the actual sampling times were not more than 2 min. The samples were centrifuged at 3000 rpm for 10 min at 37 C and the o supernatant (plasma) collected into plastic micro-tubes. o sampling.
Plasma analysis of enrofloxacin:
A quantitativequalitative agar diffusion microbiological assay using blank disks (7 mm) was employed (Kwasi et al., 1999; Ehab et al., 2008; Andres et al., 2009 ). This assay is based on the concentration-dependent variation of the inhibitory effect of antibiotics on a test bacterium, Statistical analysis on the plasma concentration-time and pharmacokinetics profiles were carried out using two-way Analysis of Variance (ANOVA). Significant difference were determined using Dunett test at p<0.05. All data were reported as mean±SEM.
RESULTS
Composite mean plasma concentrations of enrofloxacin at different time points and curves following a single oral administration of the brands at a dose level of 20 mg/kg b.w to chickens are presented in Table 1 and Fig. 1 respectively. The plasma concentrations at the time points sampled for the three brands were significantly different (p<0.05). Table 3 : In-vivo PK/PD integration parameters for enrofloxacin after a single oral administration of three brands of 10% enrofloxacin at a dose level of 20 mg/kg b.w et al. (2004) in chickens. The differences are likely due to the difference in the dosages, routes of administrations and the ingredients used in formulating these brands. Generally, the plasma pharmacokinetics profiles of enrofloxacin following administration of the three brands differed significantly (p<0.05).
------------------------------------------------------------------administration
The clinical effectiveness of Aminoglycosides and Fluoroquinolones is influenced by the height of peak plasma concentration (C ) relative to MIC (C /MIC) max max and the area under the plasma concentration-time curve that is above the MIC during the dose interval (AUIC = AUC/MIC). The former is reported to be more significant for Fluoroquinolones where maximum activity i s achieved when C is about 10 fold above the MIC max (Baggot, 2001) . Based on the above results, all the brands may perhaps be considered effective and will not lead to the emergence of resistant bacterial organisms in chickens when oral dose of 20mg/kg b.w is given to chickens.
Conclusion:
Since C /MIC ratios obtained following a max 90
single oral dose (20 mg/kg b.w) administration of the three brands are above the recommended values, it is likely that this treatment will be effective in chickens infected with common pathogenic bacterial organisms. This also suggests that chances for emergence o f resistant bacterial strains following their administrations will be minimal in this animal species.
